Lymphoproliferative disorders Clinical Trials

A listing of Lymphoproliferative disorders medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 177 clinical trials
A Study of Oral LOXO-305 in Patients With Previously Treated CLL/SLL or NHL

This is an open-label, multi-center Phase 1/2 study of oral LOXO-305 in patients with CLL/SLL and NHL who have failed or are intolerant to standard of care.

r-chop
blood transfusion
venetoclax
measurable disease
chronic lymphocytic leukemia
  • 93 views
  • 22 Sep, 2021
  • 102 locations
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors Lymphomas or Multiple Myeloma (The MATCH Screening Trial)

This phase II MATCH trial studies how well treatment that is directed by genetic testing works in patients with solid tumors or lymphomas that have progressed following at least one line of standard treatment or for which no agreed upon treatment approach exists. Genetic tests look at the unique genetic …

cutaneous squamous cell carcinoma
targeted therapy
fgfr inhibitor
ipatasertib
erdafitinib
  • 6097 views
  • 22 Sep, 2021
  • 1028 locations
Novel Combination Therapy in the Treatment of Relapsed and Refractory Aggressive B-Cell Lymphoma

The purpose of this study is to find out what effects new combinations of treatment will have this disease. New promising treatment strategies will be added to this study as they are available to be compared against the standard treatment.

b-cell lymphoma
filgrastim
cyclophosphamide
diffuse large b-cell lymphoma
chemotherapy regimen
  • 0 views
  • 20 Sep, 2021
  • 16 locations
P-BCMA-101 Tscm CAR-T Cells in the Treatment of Patients With Multiple Myeloma (MM)

Phase 1 of the study is comprised of an open-label, single ascending dose (SAD), multiple cohort study; a multiple dose cycle administration cohort study; and a combination administration study of P-BCMA-101 autologous T stem cell memory (Tscm) CAR-T cells in patients with relapsed / refractory MM. Followed by a Phase …

line of therapy
bcma
immunomodulatory imide drug
proteasome inhibitor
  • 352 views
  • 21 Sep, 2021
  • 16 locations
Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Participants With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation (SCT)

The purpose of this study is to determine the long-term safety and tolerability of ixazomib maintenance therapy.

bone marrow procedure
neutrophil count
platelet count
growth factor
cell transplantation
  • 11 views
  • 22 Sep, 2021
  • 13 locations
A Study of Daratumumab Plus Lenalidomide Versus Lenalidomide Alone as Maintenance Treatment in Participants With Newly Diagnosed Multiple Myeloma Who Are Minimal Residual Disease Positive After Frontline Autologous Stem Cell Transplant

The purpose of this study is to evaluate conversion rate to minimal residual disease (MRD) negativity following the addition of daratumumab to lenalidomide relative to lenalidomide alone, when administered as maintenance treatment to anti-cluster of differentiation 38 (CD38) treatment naive participants with newly diagnosed multiple myeloma who are MRD positive …

bone marrow procedure
progressive disease
lenalidomide
cell transplantation
daratumumab
  • 92 views
  • 24 Sep, 2021
  • 80 locations
A Study of DARZALEX (Daratumumab) In Indian Participants With Relapsed and Refractory Multiple Myeloma Whose Prior Therapy Included a Proteasome Inhibitor and an Immunomodulatory Agent

The purpose of this study is to demonstrate the safety profile of daratumumab in routine clinical practice when given as monotherapy in Indian participants with relapsed and refractory multiple myeloma, whose prior therapy included a proteasome inhibitor and an immunomodulatory agent.

refractory multiple myeloma
daratumumab
immunotherapeutic agent
proteasome inhibitor
  • 111 views
  • 22 Sep, 2021
  • 22 locations
A Study of CC-98633 BCMA-targeted Chimeric Antigen Receptor (CAR) T Cells in Subjects With Relapsed and/or Refractory Multiple Myeloma

This is a Phase 1, multicenter, open-label study of CC-98633, BCMA-Targeted NEX-T Chimeric Antigen Receptor (CAR) T Cells, in subjects with relapsed and/or refractory multiple myeloma. The study will consist of 2 parts: dose-escalation (Part A) and dose-expansion (Part B). The dose-escalation part (Part A) of the study is to …

proteasome inhibitor
lenalidomide
daratumumab
bcma
pomalidomide
  • 0 views
  • 18 Sep, 2021
  • 11 locations
Strength Training in Improving Pain and Quality of Life in Patients With Multiple Myeloma

This trial studies how well strength training works in improving bone health, pain, and quality of life in patients with multiple myeloma. Weekly physical activity may improve bone recovery, reduce pain, and increase quality of life in patients with multiple myeloma.

  • 0 views
  • 17 Sep, 2021
  • 1 location
Daratumumab Carfilzomib Lenalidomide and Low Dose Dexamethasone (DKRd) in Newly Diagnosed Multiple Myeloma

The purpose of this study is to determine response rate after 8 cycles of D-KRd (daratumumab, carfilzomib, lenalidomide (Revlimid) and dexamethasone in patients with multiple myeloma.

lenalidomide
dexamethasone
hypercalcemia
carfilzomib
measurable disease
  • 0 views
  • 24 Sep, 2021
  • 1 location